糖尿病血液透析患者中与甲氧氯普胺相关的迟发性运动障碍。两例病例报告。

Metoclopramide-associated tardive dyskinesia in hemodialysis patients with diabetes mellitus. Two case reports.

作者信息

Sewell D D, Yoshinobu B H, Caligiuri M P, Jeste D V

机构信息

University of California, San Diego.

出版信息

Gen Hosp Psychiatry. 1992 Nov;14(6):416-9. doi: 10.1016/0163-8343(92)90009-y.

DOI:10.1016/0163-8343(92)90009-y

PMID:1473712

Abstract

Metoclopramide, a drug used almost exclusively for medical indications, is a dopamine (D-2) receptor blocker and has been reported to cause extrapyramidal side effects. We present two case reports of hemodialysis patients who were treated with metoclopramide for diabetic gastroparesis. Within 12 months of beginning treatment, both patients developed persistent tardive dyskinesia. These cases highlight the fact that some patients who benefit from metoclopramide may also have a relatively high risk of developing persistent tardive dyskinesia. The consultation-liaison psychiatrist can play an important role in the education of the medical staff regarding metoclopramide-induced tardive dyskinesia.

摘要

甲氧氯普胺几乎仅用于医学适应症，是一种多巴胺（D-2）受体阻滞剂，据报道可引起锥体外系副作用。我们报告两例接受甲氧氯普胺治疗糖尿病胃轻瘫的血液透析患者。在开始治疗的12个月内，两名患者均出现持续性迟发性运动障碍。这些病例凸显了这样一个事实，即一些从甲氧氯普胺治疗中获益的患者也可能有相对较高的发生持续性迟发性运动障碍的风险。会诊联络精神科医生在就甲氧氯普胺所致迟发性运动障碍对医务人员进行教育方面可发挥重要作用。